Vivos Therapeutics Retained Earnings (Accumulated Deficit) 2020-2025 | VVOS

Vivos Therapeutics retained earnings (accumulated deficit) from 2020 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Vivos Therapeutics Retained Earnings (Accumulated Deficit) 2020-2025 | VVOS

Vivos Therapeutics retained earnings (accumulated deficit) from 2020 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.9B
Zoetis (ZTS)$67.3B
Takeda Pharmaceutical (TAK)$46.3B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$32.4B
Sandoz Group AG (SDZNY)$25.8B
Summit Therapeutics (SMMT)$19.7B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.4B
Corcept Therapeutics (CORT)$7.3B
Madrigal Pharmaceuticals (MDGL)$7B
Ionis Pharmaceuticals (IONS)$6.7B
Grifols, S.A (GRFS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Procaps Group, S.A (PROCF)$3.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B